Your browser is no longer supported. Please, upgrade your browser.
GH Guardant Health, Inc. daily Stock Chart
Guardant Health, Inc.
Index- P/E- EPS (ttm)-6.16 Insider Own7.90% Shs Outstand85.86M Perf Week27.93%
Market Cap4.38B Forward P/E- EPS next Y-1.25 Insider Trans- Shs Float41.37M Perf Month26.60%
Income- PEG- EPS next Q-0.35 Inst Own33.40% Short Float6.30% Perf Quarter35.57%
Sales77.77M P/S56.38 EPS this Y-92.90% Inst Trans52.52% Short Ratio5.04 Perf Half Y-
Book/sh-18.83 P/B- EPS next Y21.40% ROA- Target Price44.75 Perf Year-
Cash/sh3.16 P/C16.16 EPS next 5Y42.90% ROE- 52W Range27.04 - 49.55 Perf YTD35.86%
Dividend- P/FCF- EPS past 5Y- ROI42.80% 52W High3.07% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low88.87% ATR2.43
Employees348 Current Ratio9.30 Sales Q/Q95.50% Oper. Margin- RSI (14)76.88 Volatility7.35% 5.40%
OptionableNo Debt/Eq- EPS Q/Q26.60% Profit Margin- Rel Volume1.55 Prev Close48.87
ShortableYes LT Debt/Eq- EarningsNov 19 AMC Payout- Avg Volume517.30K Price51.07
Recom1.80 SMA2024.19% SMA5027.72% SMA20034.23% Volume802,263 Change4.50%
Oct-29-18Initiated William Blair Outperform
Oct-29-18Initiated JP Morgan Overweight $42
Oct-29-18Initiated BofA/Merrill Neutral $37
Feb-14-19 04:05PM  Guardant Health to Present at the 8th Annual Leerink Partners Global Healthcare Conference GlobeNewswire +13.49%
Jan-29-19 09:38AM  What's next for this slow-moving Peninsula biotech IPO? American City Business Journals
Jan-18-19 12:51PM  Do Institutions Own Guardant Health, Inc. (NASDAQ:GH) Shares? Simply Wall St.
Jan-07-19 07:00AM  Guardant Health Announces Launch of the LUNAR Assay for Detection of Early-Stage Cancer and Recurrence to Academic and Biopharmaceutical Researchers GlobeNewswire +5.36%
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals -5.30%
Dec-20-18 07:00PM  Guardant Health to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-13-18 12:15PM  Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi GlobeNewswire
Dec-03-18 03:31PM  The Probable Reason Guardant Health Is Soaring Today Motley Fool +28.58%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-19-18 04:29PM  Guardant Health reports first earnings since IPO MarketWatch -9.74%
04:05PM  Guardant Health Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-13-18 04:03PM  Guardant Health To Report Third Quarter Financial Results on November 19, 2018 GlobeNewswire
Nov-01-18 02:51PM  Where SoftBanks Vision Fund is deploying its $100 billion Yahoo Finance
Oct-31-18 03:34PM  Strong IPO pace continued in October but some cracks are showing American City Business Journals
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals -6.86%
Oct-19-18 08:00AM  Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting PR Newswire -10.77%
Oct-16-18 08:00AM  Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations PR Newswire +13.04%
Oct-15-18 02:02PM  Unicorn births outpace IPOs in Bay Area: Here are the 24 new ones so far this year American City Business Journals
Oct-09-18 04:03PM  Guardant Health Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire +6.63%
Oct-05-18 08:00AM  Todays Research Reports on Stocks to Watch: Guardant Health and Vaxart ACCESSWIRE -9.32%
Oct-04-18 02:15PM  Nasdaq Welcomes Guardant Health, Inc. (Nasdaq: GH) to The Nasdaq Stock Market GlobeNewswire
11:01AM  Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early MarketWatch
10:55AM  Guardant Health's stock soars in public debut after IPO prices above expectations MarketWatch
09:02AM  Guardant Health IPO prices above expected range to value company at $1.6 billion MarketWatch
Oct-03-18 07:38PM  Guardant Health Announces Pricing of Initial Public Offering GlobeNewswire
Sep-30-18 09:41AM  IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators Benzinga
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.